THANKS BUT NO THANKS (THE THIRD)
I'd rather continue quoting the facts about RXMD, namely its year-plus of double-digit YoY revenue increases (up to and including March 2017), its being on-track to achieve its 2017 revenue goal of $22 million, its profitability, its third-party-audited financials, and so on.
Please, tell us again how you expected RXMD to earn exactly 25% of its annual revenues in Q1, when RXMD hasn't earned more than 23% of annual revenues in Q1 in at least three years, and that figure was down to 21.5% for 2016.
GARBAGE IN, GARBAGE OUT